SCHEMBL1845376

SCHEMBL1845376

Nc1cc(Cl)nc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 2/20 0.60
ACHE P22303 2/20 0.58
KDM4E B2RXH2 5/20 0.50
ALDH1A1 P00352 4/20 0.50
HPGD P15428 4/20 0.50
GLA P06280 3/20 0.50
HSD17B10 Q99714 3/20 0.50
MAOA P21397 2/20 0.50
CASP1 P29466 2/20 0.50
CASP7 P55210 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CHRM2 P08172 1/20 0.50
ADRA2A P08913 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
CHRM1 P11229 1/20 0.50
NQO2 P16083 1/20 0.50
DRD1 P21728 1/20 0.50
SLC6A2 P23975 1/20 0.50
ADRA1A P35348 1/20 0.50
OPRM1 P35372 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29850612 1.00 NCF1 (0.60) NCF1ACHEKDM4EALDH1A1HPGD
SCHEMBL8430983 0.79 NCF1 (0.55) NCF1ACHEKDM4EALDH1A1HPGD
SCHEMBL29420516 0.78 MAOA (0.54) ACHEKDM4EALDH1A1HPGDGLA
SCHEMBL397020 0.78 MAOA (0.54) ACHEKDM4EALDH1A1HPGDGLA
SCHEMBL29690490 0.78 NCF1 (0.64) NCF1ACHEKDM4EALDH1A1HPGD
SCHEMBL323374 0.78 NCF1 (0.64) NCF1ACHEKDM4EALDH1A1HPGD
SCHEMBL1240101 0.76 LOXL2 (0.48) ACHEKDM4EALDH1A1HPGDGLA
SCHEMBL3968023 0.75 MAOA (0.50) ACHEKDM4EALDH1A1HPGDGLA
SCHEMBL6457778 0.75 KDM4E (0.51) KDM4EALDH1A1MAOANQO2MAOB
SCHEMBL11343689 0.75 KMT2A (0.53) ACHEKDM4EALDH1A1HPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7153865-B2 N-type calcium channel antagonists for the treatment of pain ASTRAZENECA AB (SE) 2006-12-26 US claimed
US-7060834-B2 N-type calcium channel antagonists for the treatment of pain ASTRAZENECA AB (SE) 2006-06-13 US claimed
US-20050131020-A1 N-type calcium channel antagonists for the treatment of pain ASTRAZENECA AB (SE) 2005-06-16 US claimed
EP-1430030-B1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2005-05-18 EP claimed
US-20040266819-A1 N-type calcium channel antagonists for the treatment of pain ASTRAZENECA AB (SE) 2004-12-30 US claimed
EP-1430030-A1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2004-06-23 EP claimed
EP-1430029-A1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2004-06-23 EP claimed
WO-2003018561-A1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2003-03-06 WO claimed
WO-2003018560-A1 N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2003-03-06 WO claimed
US-4421920-A AMINATION, AROMATIZATION, RUTHENIUM CATALYST RHONE-POULENC SANTE (FR) 1983-12-20 US claimed
CN-119585263-A Phenyl substituted dihydro Cai compounds and preparation and application thereof 苏中药业集团股份有限公司 2025-03-07 CN disclosed
WO-2025011008-A1 PHARMACEUTICAL PREPARATION CONTAINING PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUND, AND USE THEREOF 苏中药业集团股份有限公司 2025-01-16 WO disclosed
CN-119302952-A Pharmaceutical preparation containing phenyl substituted dihydronaphthyridine compound and application thereof 苏中药业集团股份有限公司 2025-01-14 CN disclosed
CN-119306715-A Crystal of phenyl substituted dihydronaphthyridine compound and application thereof 苏中药业集团股份有限公司 2025-01-14 CN disclosed
WO-2024022481-A1 PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUNDS, AND PREPARATION AND USE THEREOF 苏中药业集团股份有限公司 2024-02-01 WO disclosed
US-4966954-A VOLATILE BY-PRODUCT-FREE, CYCLIAZABLE POLYAMINESS BASED ON AROMATIC DIAMINES AND AROMATIC BIS(2-CYANO-1-HALOVINYL) DERIVATIVES; NONHYDROLYZING; DIELECTRICS; THIN FILMS RENSSELAER POLYTECHNIC INSTITUTE (US) 1990-10-30 US disclosed
US-4421920-A AMINATION, AROMATIZATION, RUTHENIUM CATALYST RHONE-POULENC SANTE (FR) 1983-12-20 US disclosed
US-4421920-A AMINATION, AROMATIZATION, RUTHENIUM CATALYST RHONE-POULENC SANTE (FR) 1983-12-20 US disclosed
US-4421920-A AMINATION, AROMATIZATION, RUTHENIUM CATALYST RHONE-POULENC SANTE (FR) 1983-12-20 US disclosed
EP-0056766-A1 Process for the preparation of 4-amino-chloroquinolines RHONE-POULENC SANTE (FR) 1982-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266819-A1 N-type calcium channel antagonists for the treatment of pain CACNA1E, CACNA1B, CACNA1G NCF1 396/4885ACHE 208/4885KDM4E 4507/4885
US-20050131020-A1 N-type calcium channel antagonists for the treatment of pain CACNA1E, CACNA1B, CACNA1A NCF1 511/4885ACHE 152/4885KDM4E 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.